Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343691 | 0.87 | MCHR1 (0.44) | NPC1RAB9AMCHR1ITGB3ITGA2B | |
| SCHEMBL6336525 | 0.86 | TRPV4 (0.43) | NPC1RAB9AMCHR1ITGB3ITGA2B | |
| SCHEMBL6345820 | 0.86 | TRPV4 (0.43) | NPC1RAB9AMCHR1ITGB3ITGA2B | |
| SCHEMBL3392011 | 0.85 | TRPV4 (0.42) | NPC1RAB9AMCHR1ITGB3ITGA2B | |
| SCHEMBL6345247 | 0.84 | MCHR1 (0.46) | MCHR1ITGB3ITGA2BTRPV4 | |
| SCHEMBL3386929 | 0.84 | GPR119 (0.48) | NPC1RAB9ATRPV4 | |
| SCHEMBL3392015 | 0.84 | MCHR1 (0.42) | NPC1RAB9AMCHR1ITGB3ITGA2B | |
| SCHEMBL3385427 | 0.84 | ITGB3 (0.49) | NPC1RAB9AMCHR1ITGB3ITGA2B | |
| SCHEMBL3388539 | 0.81 | DRD2 (0.38) | MCHR1ITGB3ITGA2BDRD3 | |
| SCHEMBL3385431 | 0.78 | ITGB3 (0.46) | NPC1RAB9AMCHR1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453805-B1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-6864266-B2 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1453805-A1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | BROTHERTON-PLEISS CHRISTINE E (US) | 2004-05-13 | — | — | US | disclosed |
| US-6627644-B2 | Muscarinic receptor antagonists and parasympathetic nervous system. The physiological actions of Acetylcholine are mediated by activation of either nicotinic or muscarinic receptors | SYNTEX (U.S.A.) LLC | 2003-09-30 | — | — | US | disclosed |
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) LLC, NAME CHANGED TO ROCHE PALO ALTO LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003048124-A1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM1, CHRM3, CHRM2 | NPC1 1411/4885RAB9A 1305/4885MCHR1 61/4885 |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | CHRM1, CHRM3, CHRM2 | NPC1 1411/4885RAB9A 1305/4885MCHR1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.